The innovative cancer drug RASONQUE™ (daraxonrasib) is now available to patients through Sapir Medical Clinic.
On August 26, 2026, the U.S. Food and Drug Administration (FDA) approved RASONQUE™ for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior line of systemic therapy or are unable to receive multi-agent systemic therapy.
RASONQUE™ belongs to a new class of targeted cancer therapies. It inhibits proteins from the RAS GTPase family, which play a key role in the development and progression of many pancreatic tumors.
How Sapir Medical Helps International Patients
For more than 17 years, Sapir Medical has provided comprehensive medical assistance to international patients seeking advanced diagnosis and treatment in Israel.
Our team:
- promptly arranges consultations with leading Israeli doctors and internationally renowned medical professors, including online consultations;
- coordinates comprehensive diagnostic procedures, cancer treatment and surgical care at leading hospitals in Israel;
- assists patients with purchasing and arranging the international delivery of innovative medications;
- provides personalized support throughout every stage of diagnosis and treatment.
For more information about pancreatic cancer treatment in Israel, access to RASONQUE™, or the purchase and international delivery of medications, please contact Sapir Medical: info@sapirmedical.com